Given the possible effects of C3 on clot structure and fibrinolysis, whereby it binds to fibrin and is incorporated into the clot resulting in prolonged fibrinolysis16 as well as the role of HNF1A-MODY in modulation of terminal complement proteins,17 this may be one mechanism by which to explain the differences seen between our patients with HNF1A-MODY and those with T2DM. Here, C3 is linked to type 2 diabetes mellitus.